Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
about
Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled studyPulmonary infections in the returned traveller.Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 years of age and older.Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
P2860
Q33434855-D5CEFC6A-E231-4E41-99C5-1C8BBB403C94Q33801976-BF9F7094-4053-4D55-9DE6-114A884AE566Q37375872-275B5ADF-AB6B-49F9-9FFD-C397EC57B849Q39157024-DB5CD2B6-ADBC-4A73-9E9B-AA3B86BB9C5FQ40138220-D71F762A-9903-47A4-AF96-BE87B02B2515Q41995736-BC87F635-8A2A-4D60-A855-A3CC508854EEQ47625853-7EA63818-B7E2-44EB-831C-828E70FE18CCQ49057993-C29B1B2B-2365-45D9-B722-2E8B7F2B1E86Q50420352-67BBD0E3-7047-4B73-8160-60B4FCB94B87Q52579975-2ED65032-8C19-41A6-9B85-FA4214253289Q54626497-F393DE23-F7A6-4C16-8E3A-F68392DEEED2
P2860
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety, immunogenicity, and lo ...... , controlled, phase III trial.
@en
type
label
Safety, immunogenicity, and lo ...... , controlled, phase III trial.
@en
prefLabel
Safety, immunogenicity, and lo ...... , controlled, phase III trial.
@en
P2093
P1433
P1476
Safety, immunogenicity, and lo ...... d, controlled, phase III trial
@en
P2093
Charissa Fay Borja-Tabora
Ferdinandus J de Looze
Jaime Santos
Josefina B Cadorna-Carlos
M Cecilia Montalban
Martin Dupuy
Melanie Saville
Peter Eizenberg
Stephen Hall
Stéphanie Pépin
P304
P356
10.1016/J.VACCINE.2015.03.065
P407
P50
P577
2015-04-02T00:00:00Z